The safety and efficacy of formoterol (Oxis®) Turbuhaler® plus budesonide (Pulmicort®) Turbuhaler in mild to moderate asthma: A comparison with budesonide Turbuhaler alone and current non-corticosteroid therapy in Russia

International Journal of Clinical Practice

Volumn 56, Issue 1, 2002, Pages 15-20

  Chuchalin, A G ^a   Ovcharenko, S I ^a   Goriachkina, L A ^a,a   Sidorenko, I V ^a   Tsoi, A N ^a   Alekseev, V G ^a   Bart, B Y ^a   Borisova, N K ^a   Belousov, Y B ^a   Golovko, M G ^a   Chereiskaya, N K ^a   Daniliak, I G ^a   Didkovsky, N A ^a   Dobrotina, I S ^a   Emelyanov, A V ^a   Korovina, O V ^a   Mamtsev, B N ^a   Sokurenko, S I ^a   Valekjanina, T G ^a   Zadionchenko, V S ^a  

^a Research Institute of Pulmonology   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; EXPECTORANT AGENT; FORMOTEROL; GLUCOCORTICOID ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MUCOLYTIC AGENT; NEDOCROMIL SODIUM; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; XANTHINE DERIVATIVE;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOTHERAPY; INCIDENCE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PARALLEL DESIGN; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUSSIAN FEDERATION; SYMPTOMATOLOGY; TREMOR;

ADMINISTRATION, INHALATION; ADULT; AGED; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PEAK EXPIRATORY FLOW RATE; RUSSIA; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 0036156331     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Global Initiative for Asthma
2. Short-acting β-agonists: To be taken regularly or as needed?
3. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
4. Effect of inhaled formoterol and budesonide on exacerbations of asthma
5. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma
6. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma
7. Functional and binding characteristics of long-acting β2-agonists in lung and heart
8. A randomized, double-blind, placebo-controlled, dose-response study with formoterol Turbuhaler®
9. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: Onset of action, duration of effect and potency
10. 2-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators
11. Declaration of Helsinki: Recommendations guiding medical doctors in biomedical research involving human subjects
12. Formoterol (Oxis®) Turbuhaler® plus budesonide Turbuhaler® and budesonide alone improve health-related quality of life vs non-steroid therapy in mild to moderate asthma in Russia
13. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma
14. 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma
15. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: A randomised, double-blind, parallel-group controlled trial
16. 2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma
17. Formoterol 90 mg via Turbuhaler® was safe in patients with acute bronchoconstriction
18. Tolerability to high doses of formoterol and terbutaline via Turbuhaler® for 3 days in stable asthmatic patients
19. Non-pulmonary effects induced by the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma
20. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma
21. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma
22. Oxis® (formoterol given by Turbuhaler®) showed as rapid an onset of action as salbutamol given by a pMDI
23. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma
24. Changes in specific airway resistance (sRAW) in moderate asthma after inhalation of formoterol or salmeterol dry-powder formulations
25. Use of formoterol (Oxis®) Turbuhaler® as needed in moderate to severe asthma reduces the number of inhalers used whilst maintaining effectiveness
26. As needed medication in asthma: A randomised trial comparing formoterol, a long-acting β-agonist, with terbutaline